Compare Davita Inc (DVA) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.78 (market cap $79.91B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 6.8× Davita Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.19% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MDLZ | |
|---|---|---|
Market Cap | $11.72B | $79.91B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $64.99 |
52-Week Low | $103.87 | $51.51 |
Enterprise Value | $24.44B | $100.25B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
MDLZ trades at $62.61, down 0.22% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q2 2026 earnings beat estimates with EPS of $0.73 versus $0.68 expected, driven by 2.2% organic revenue growth. The company raised its 2026 organic sales outlook, supported by strength in emerging markets and improved execution in North America. Cash flow from operations remains robust at $4.5 billion in 2025, though net income margin dipped to 6.36% from higher costs.
Outlook is positive with a consensus price target of $70.50, implying 12.6% upside, and 76% of analysts rate it a buy. Risks include reliance on international sales exposure to currency fluctuations and competitive pressures in the snack industry. Valuation multiples like P/E of 38.25 appear elevated relative to historical norms, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
